Jump to:
Corporate associate Nicole Rohr joined Ropes & Gray’s Boston office in 2021.
During law school, Nicole was the executive notes & comments editor for the Roger Williams University Law Review. She was also an active member of the Women’s Law Society, serving as secretary for the 2015-2016 term and vice president for the 2016-2017 term. Following graduation, Nicole clerked for Justice Maria Kahn of the Connecticut Supreme Court and Judge Thomas O. Farrish of the U.S. District Court for the District of Connecticut.
Prior to joining the firm, Nicole was the assistant director and assistant research professor of the Coastal Institute at the University of Rhode Island. She has also served members of the U.S. Senate and U.S. House of Representatives as a legislative assistant, providing guidance on issues ranging from energy and environment to climate change to agriculture. Nicole holds a Ph.D. in biological sciences and has over 10 years of academic and government experience.
Experience
- Advised Monte Rosa Therapeutics in a global exclusive licensing agreement with Novartis to develop and commercialize a molecular glue degrader drug for immune-related diseases.
- Advised Adaptimmune Therapeutics in a clinical collaboration agreement with Galapagos NV, valued at up to $665 million, with an option to exclusively license Adaptimmune’s next-generation engineered T-cell receptor (TCR) T-cell therapy, called uza-cel, targeting certain head and neck cancer and potential future solid tumor indications using Galapagos’ decentralized cell manufacturing platform.
- Advised Nona Biosciences, a company focused on antibody discovery services, in numerous transactions including:
- in a license agreement with AstraZeneca, valued at up to $604 million, for preclinical monoclonal antibodies that will be used to develop targeted oncology therapies using Nona’s antibody discovery platform.
- in an exclusive license agreement with Pfizer (Seagen), valued at up to $1.58 billion, for the rights to Nona’s mesothelin-targeted antibody-drug candidate HBM9033.
- Advised Parma, Italy-based biopharmaceutical company Chiesi Group in a global strategic collaboration with Gossamer Bio, valued at up to $486 million, to develop and commercialize Gossamer’s pulmonary arterial hypertension treatment seralutinib.
- Advised Xeris Biopharma Holdings in an exclusive worldwide collaboration and license agreement with Beta Bionics for the development and commercialization of a glucagon product using Xeris’ XeriSol technology for use in Beta Bionics’ proprietary bi-hormonal pump and pump systems for people with diabetes.
- Advised Allorion Therapeutics in a global licensing agreement with Avenzo Therapeutics, valued at up to $1.4 billion, to develop and commercialize Allorian’s AVZO-021, a cyclin-dependent kinase 2 selective inhibitor, globally, excluding Greater China.
- Advised Fauna Bio in a multi-year strategic collaboration agreement with pharmaceutical leader Eli Lilly and Company, valued at up to $494 million, that applies Fauna’s Convergence artificial intelligence (AI) platform to support preclinical drug discovery in obesity.
- Represented Avidity Biosciences in a global licensing and research collaboration with Bristol Myers Squibb focused on the discovery, development and commercialization of RNA therapeutics directed to multiple cardiovascular targets with potential cumulative payments up to $2.3 billion.
- Represented ImmunoGen, Inc., a leader in the field of antibody-drug conjugates, in an exclusive collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize Immunogen’s ADC therapy ELAHERE in Japan.
- Advised Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc., a specialty biopharmaceutical company focused on bone health, in a Royalty Purchase Agreement for a portion of Radius’s royalty and commercial milestone stream in elacestrant, a treatment approved for certain types of mutated advanced or metastatic breast cancer, with DRI Healthcare Acquisitions LP (DRI) valued at up to $340 million.
- Represented Cullinan Oncology in an exclusive license agreement with Harbour BioMed, valued at up to $588 million, for the development and commercialization rights to HBM7008 (CLN-418), a B7H4 x 4-1BB bispecific immune activator, currently in a Phase 1 clinical trial in U.S. and Australian sites in patients with advanced solid tumors.
- Advised Ovid Therapeutics in a strategic partnership with U.K.-based Healx, an AI-powered technology company, that granted Healx the exclusive option to license rights to develop and commercialize gaboxadol.
- Advised a major biopharmaceutical company in connection with a gene editing pact with hopes of producing treatments for two undisclosed genetic diseases.
- Advised iCapital Network in a definitive agreement to acquire Axio Financial LLC.
- Represented a major biopharmaceutical company in connection with a global strategic, gene therapy collaboration agreement.
- Advised McAfee Corp. in a definitive agreement to sell its Enterprise business to a consortium led by Symphony Technology Group in an all-cash transaction for $4 billion.
- Represented HP Inc. in its $425 million acquisition of HyperX, the gaming division of Kingston Technology Company.